September is Ovarian Cancer Awareness Month. According to the Centers for Disease Control and Prevention (CDC), ovarian cancer is the second most common gynecologic cancer in the United States and causes more deaths than any other cancer of the female reproductive system.

In this article, we will be taking a look at the current clinical practice guidelines for ovarian cancer and related topics.

Ovarian Cancer – Clinical Practice Guidelines:

Ovarian Cancer – Medications:

There has only been one major new FDA approval for treatment of ovarian cancer since 2022:

  • Elahere (mirvetuximab soravtansine-gynx) – ImmunoGen (November 2022)
    • For adult patients with folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

Looking Ahead:

As we look ahead towards National Ovarian Cancer Awareness Month 2024, there will be multiple focused updates to existing Ovarian Cancer clinical guidelines, as well as a few new guidelines.

  • ASCO NACT for Newly Diagnosed, Advanced Ovarian Cancer
  • ASCO First Platinum-Sensitive Ovarian Cancer Recurrence
  • ASCO Gynecologic Cancers Survivorship
  • NCCN Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer

That’s it for our recap of this year’s National Ovarian Cancer Month 2023. Did we miss anything? If so, let us know. Also let us know which awareness month you’d like to see us cover next in our ongoing series.

Copyright © 2023 Guideline Central, All rights reserved.